胶质瘤中LYRM4AS1的表达及预后独立危险因子作用研究  

The study on expression of LYRM4-AS1 and independent risk factor in glioma

作　　者：王海月 宋菲 任鹏 谢颖[1] 李增宁[1] 骆彬[1] Wang Haiyue;Song Fei;Ren Peng;Xie Ying;Li Zengning;Luo Bin(Department of Clinical Nutrition,the First Hospital of Hebei Medical University,Shijiazhuang 050031,Hebei,China)

机构地区：[1]河北医科大学第一医院营养科,石家庄050031

出　　处：《肿瘤代谢与营养电子杂志》2021年第4期414-419,共6页Electronic Journal of Metabolism and Nutrition of Cancer

基　　金：国家自然科学基金面上项目(81773430);河北省政府资助优秀人才项目(LS202002);河北省医学科学研究课题(20190454)。

摘　　要：目的评估LYRM4‐AS1在胶质瘤患者中的表达水平和临床意义,以及其相关机制。方法从TCGA数据库收集胶质瘤患者的RNA‐seq数据与临床资料,研究LYRM4‐AS1在肿瘤组织与正常组织中的表达情况,分析其与胶质瘤患者临床病理特征的关系。通过Kaplan‐Meier生存曲线和Cox回归分析,评估LYRM4‐AS1的临床意义,对LYRM4‐AS1潜在的生物学机制进行探讨。结果相比于正常组织,LYRM4‐AS1在多种肿瘤组织中高表达,并且与胶质瘤患者的世界卫生组织(WHO)等级(P<0.001)、IDH状态(P<0.001)、1p/19q编码缺失(P<0.001)、初始治疗结果(P<0.001)、表皮生长因子受体状态(P<0.001)和年龄(P<0.001)具有相关性。预后分析发现,LYRM4‐AS1高表达胶质瘤患者具有更短的总生存期(HR=3.99,95%CI=3.01~5.30,P<0.001),无进展间隔生存期(HR=2.68,95%CI=2.13~3.38,P<0.001)和疾病特异性生存期(HR=4.00,95%CI=2.98~5.37,P<0.001)和PFI(HR=2.68,95%CI=2.13~3.38,P<0.001)。多因素Cox回归分析发现,LYRM4‐AS1为预后独立危险因子。功能富集分析发现,LYRM4‐AS1与炎症和免疫反应相关。结论LYRM4‐AS1可能是潜在的诊疗及预后标志物,并且其可能通过炎症与免疫反应在胶质瘤发生发展中发挥作用。Objective To evaluate the expression level and clinical significance of LYRM4-AS1 in glioma patients,as well as its related mechanisms.Methods RNA-seq data and clinical data of glioma patients were obtained from the TCGA database.The expression of LYRM4-AS1 in tumor and normal tissues was studied,and then the relationship between LYRM4-AS1 and the clinicopathological characteristics of patients with glioma was analyzed.Kaplan-Meier survival curve and Cox regression analysis were used to evaluate the clinical significance of LYRM4-AS1.The potential biological mechanism of LYRM4-AS1 was discussed through functional enrichment analysis.Results The study found that compared with normal tissues,LYRM4-AS1 was highly expressed in a variety of tumor tissues,and was related to WHO grade(P<0.001),IDH status(P<0.001),and 1p/19q coding loss(P<0.001),primary therapy outcome(P<0.001),EGFR status(P<0.001)and age(P<0.001).Prognostic analysis found that glioma patients with LYRM4-AS1 overexpressing had worse OS(HR=3.99,95%CI=3.01-5.30,P<0.001),DSS(HR=4.00,95%CI=2.98-5.37,P<0.001)and PFI(HR=2.68,95%CI=2.13-3.38,P<0.001).Multivariate Cox regression found that LYRM4-AS1 was an independent risk factor for prognosis.Finally,functional enrichment analysis found that LYRM4-AS1 was related to inflammation and immune response.Conclusion LYRM4-AS1 may be a potential diagnosis,treatment and prognostic marker,and it may play a role in the occurrence and development of glioma through inflammation and immune response.

关 键 词：LYRM4‐AS1 胶质瘤 预后 生物信息学分析 

分 类 号：R739.41[医药卫生—肿瘤]